Fierce Biotech

BridgeBio preps approval push after dwarfism drug increases children's height in phase 3

BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...
BioSpace

Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study

Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.
CURE

FDA Clears Phase 3 Trial of iSCIB1+ for Advanced Melanoma Treatment

The FDA approved Scancell's phase 3 trial of iSCIB1+ for advanced melanoma, focusing on progression-free survival as a ...

PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
Business Wire

Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan ...
The American Journal of Managed Care

Zasocitinib Hits Phase 3 End Points in Plaque Psoriasis

Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...
Nasdaq

Intellia Therapeutics Doses First Patient in Phase 3 HAELO Study for NTLA-2002 and Updates on Clinical Trials and Financial Results

Intellia Therapeutics details progress in Phase 3 trials for NTLA-2002 and nex-z, anticipating key regulatory submissions by 2026. Intellia Therapeutics has announced the initiation of the global ...
Healio

Few phase 3 oncology trials demonstrate improvements in OS, quality of life

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of alternative endpoints in phase 3 oncology trials ...
Business Wire

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common ...